Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.

Whereas response rate only showed a trend to be higher in patients with Her-2/ neu -phosphorylated breast cancer (47 vs 34%, P =0.197), both uni- and multivariate analyses revealed that the median progression-free survival under trastuzumab-based treatment was significantly longer in patients with Her-2/ neu -phosphorylated breast cancer–11.7 (95% CI 5.2–18.3) months–when compared to the progression-free survival of 4.5 (95% CI 3.4–5.6) months observed in patients with tumours lacking phosphorylated Her-2/ neu ( P =0.001).

also in 53,322 other papers